Norbrook Meloxicam 0.5mg/ml Oral Suspension for Cats

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Meloxicam

Available from:

Norbrook Laboratories Limited

ATC code:

QM01AC06

INN (International Name):

Meloxicam

Pharmaceutical form:

Oral suspension

Prescription type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutic group:

Cats

Therapeutic area:

Anti Inflammatory NSAID

Authorization status:

Authorized

Authorization date:

2016-02-11

Summary of Product characteristics

Revised: December 2022
AN: 02473/2022
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Norbrook Meloxicam 0.5mg/ml Oral Suspension for Cats
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE:
Meloxicam
0.5 mg
EXCIPIENT:
Sodium benzoate
1.5 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral suspension
Pale yellow suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Alleviation of mild to moderate post-operative pain and inflammation
following
surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.
Alleviation of inflammation and pain in acute and chronic
musculo-skeletal disorders
in cats.
4.3
CONTRAINDICATIONS
Do not use in pregnant or lactating cats.
Do not use in cats suffering from gastrointestinal disorders such as
irritation and
haemorrhage, impaired hepatic, cardiac or renal function and
haemorrhagic
disorders.
Do not use in case of hypersensitivity to the active substance or to
any of the
excipients
Do not use in cats less than 6 weeks of age.
Revised: December 2022
AN: 02473/2022
Page 2 of 6
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
If adverse reactions occur, treatment should be discontinued and the
advice of a
veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as
there is a
potential risk of renal toxicity.
Post-operative pain and inflammation following surgical procedures:
In case additional pain relief is required, multimodal pain therapy
should be
considered.
Chronic musculoskeletal disorders:
Response to long-term therapy should be monitored at regular intervals
by a
veterinary surgeon.
Special precautions to be taken by the person administering the
veterinary medicinal
product to animals
People with known hypersensitivity to non-steroidal anti-inflammatory
drugs
(NSAIDs) should avoid contact with the